On-Demand Events



Emerging Therapies for the Management of Castration-Sensitive Prostate Cancer
Prostate cancer is the second most common cancer, after skin cancer, among men. It is the second leading cause of cancer death in the United States. With the recent drug approvals and updates to clinical practice guidelines, several knowledge, competence, and performance gaps exist in the optimal management of metastatic castration-sensitive prostate cancer (mCSPC).

This webinar addresses some of the challenges in optimal sequencing of care in mCSPC and strategies for translating new research into patient care strategies.


This activity was in collaboration with the Association of Community Cancer Centers (ACCC).

Characterizing and Targeting a Tumor Immune Microenvironment in FGFR-Mutated Bladder Cancer
Novel immunotherapy drugs are used to treat advanced bladder cancer when chemotherapy is no longer working. However, only one in five patients responds to immunotherapy, likely due to biological differences in bladder cancer. Hear Andreev-Drakhlin, MD, University of Texas MD Anderson Cancer Center—recipient of The ASCO Foundation 2020 Conquer Cancer Young Investigator Award—present his research plans in using fibroblast growth factor receptor (FGFR) inhibitors for improving the effectiveness of immunotherapy for bladder cancer.



TxSCO Virtual Annual Conference
The TxSCO Annual Conference featured three days of virtual content, which traversed the current immunotherapy landscape in renal cell carcinoma, unveiled innovations in CAR T-cell therapies, shared business strategies for strengthening oncology operations, and explored the past, present, and future of value-based care.


ASCO Highlights and More: Investigators Review Recent Data Sets and Provide Perspectives on Current Oncology Care
The Texas Society of Clinical Oncology partnered with Dr. Neil Love and Research To Practice (RTP) to host a daylong virtual program reviewing the current management strategies and recent advances in breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and lung cancer. 

With a focus on the ASCO Annual Meeting, faculty delivered a series of mini presentations quickly summarizing the most important points from more than 60 recently released papers. To enhance our discussion of the data, nearly 50 challenging cases were presented from TxSCO clinicians throughout the day, providing practical considerations for translating these results into day-to-day decision-making.


ACCCeLearning-OSS - 500x135

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us